adroparin use in critically ill patients on the ICU ward: safe and steady form of coagulation?

Recruiting

• Conditions: bleeding diathesis; hemostasis; 10064477; 10029149

• Registration Number: NL-OMON33800
• Lead Sponsor: Medisch Centrum Alkmaar

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 120

Inclusion Criteria

1. Patient with minimum age of 18 years and expected admission time on the ICU of minimum of 48 hours
2. Patient with prophylactic or therapeutic dosage of nadroparin daily

Exclusion Criteria

1. thrombocytopenia (<30)
2. heparin induced trombocytopenia and trombosis HITT
3. bleeding diathesis in which the use of nadroparin is contraindicated
4. use of unfractioned heparin exept during dialysis
5. pregnancy

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Anti-Xa activity</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Bleeding diathesis<br /><br>Thrombosis</p><br>